15-min delayed · Jul 27, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 4 firms covering Recursion Pharmaceuticals Inc, 2 rate it Buy or better, 2 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets span $5.50 to $10.00, a moderate spread. The average target of $7.38 sits 144% above the current $3.02. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.23 next quarter toward $-0.94 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS4 ratings
Moderate Buy
Strong Buy00%
Buy250%
Hold250%
Sell00%
Strong Sell00%
Based on 4 analysts giving stock ratings to Recursion Pharmaceuticals Inc.
As of Jul, 2 of 4 firms rate RXRX a Buy (2 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
RXRX EPS & revenue forecast
EPS · NEXT QUARTER
$-0.23
Range $-0.25 – $-0.20 · 5 analysts · -36% YoY
Next period, 5 analysts expect Recursion Pharmaceuticals Inc to earn $-0.23 a share (range $-0.25 – $-0.20), versus $-0.36 a year earlier. Full-year consensus is $-0.92, growing to $-0.94 the year after.
REVENUE · NEXT QUARTER
$20.6M
Range $12.0M – $30.2M · 5 analysts · +298% YoY
Revenue is expected to reach $20.6M (range $12.0M – $30.2M), +297.5% year-over-year. Full-year consensus is $64.7M, rising to $83.8M next year.
Top analysts covering Recursion Pharmaceuticals Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on RXRX.
#1
Gil Blum
Needham · Rank #298
Buy
$8.00+165.0% to target
Overall win rate
24%
+ Follow
#2
Scott Schoenhaus
Keybanc · Rank #345
Buy
$10.00+231.2% to target
Overall win rate
29%
+ Follow
#3
VP
Vikram Purohit
Morgan Stanley
Hold
$5.50+82.2% to target
Coverage
—
+ Follow
#4
Mani Foroohar
Leerink Partners
Hold
No targeton RXRX
Coverage
—
+ Follow
#5
PG
Priyanka Grover
JP Morgan
Buy
$10.00+231.2% to target
Coverage
—
+ Follow
RXRX stock forecast FAQ
What is RXRX's average 12-month price target?+
The 4 analysts with a live target average $7.38 for Recursion Pharmaceuticals Inc over the next 12 months, ranging from a $10.00 high to a $5.50 low.
Is RXRX stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 4 analyst ratings, 2 are Buy or Strong Buy, 2 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for RXRX?+
The Street-high target is $10.00 (JP Morgan), and the Street-low is $5.50 (Morgan Stanley). The average of all 4 active targets is $7.38.
How many Wall Street analysts cover RXRX?+
4 analysts have an active rating on Recursion Pharmaceuticals Inc, and 4 firms carry a live 12-month price target.
Who is the most accurate analyst covering RXRX?+
Among analysts who currently cover RXRX, Gil Blum of Needham has the strongest overall Quantellect track record (Rank #298). Their current call is Buy with a $8.00 target.
What is Recursion Pharmaceuticals Inc's projected EPS for next quarter?+
The consensus estimate is $-0.23 per share (range $-0.25 – $-0.20) across 5 analysts. Full-year EPS is projected at $-0.92, rising to $-0.94 the following year.
How much revenue is Recursion Pharmaceuticals Inc expected to report next quarter?+
Consensus revenue is $20.6M (range $12.0M – $30.2M). Full-year revenue is projected at $64.7M, growing to $83.8M next year.
Have analysts been upgrading or downgrading RXRX lately?+
As of Jul, 2 of 4 firms rate RXRX a Buy (2 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their RXRX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
